Daniel Grosslight
Stock Analyst at Citigroup
(1.29)
# 3,166
Out of 5,133 analysts
114
Total ratings
38.03%
Success rate
-11.51%
Average return
Main Sectors:
Stocks Rated by Daniel Grosslight
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAY Waystar Holding | Maintains: Buy | $49 → $46 | $30.58 | +50.43% | 3 | Jan 9, 2026 | |
| TDOC Teladoc Health | Maintains: Neutral | $10 → $9 | $6.99 | +28.76% | 13 | Jan 9, 2026 | |
| PHR Phreesia | Maintains: Buy | $29 → $25 | $16.58 | +50.78% | 8 | Jan 9, 2026 | |
| HCAT Health Catalyst | Maintains: Neutral | $3.25 → $2.75 | $2.40 | +14.58% | 12 | Jan 9, 2026 | |
| GDRX GoodRx Holdings | Maintains: Buy | $5 → $4.5 | $2.86 | +57.34% | 8 | Jan 9, 2026 | |
| EVH Evolent Health | Maintains: Buy | $9.5 → $6 | $4.01 | +49.63% | 6 | Jan 9, 2026 | |
| CTEV Claritev | Maintains: Buy | $80 → $63 | $32.42 | +94.32% | 4 | Jan 9, 2026 | |
| ACH Accendra Health | Maintains: Buy | $7 → $4 | $2.51 | +59.36% | 1 | Jan 9, 2026 | |
| CAH Cardinal Health | Upgrades: Buy | $190 → $244 | $208.26 | +17.16% | 11 | Jan 9, 2026 | |
| MCK McKesson | Maintains: Buy | $820 → $860 | $823.98 | +4.37% | 8 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 → $1 | $0.95 | +5.26% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $25 → $30 | $32.20 | -6.83% | 11 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $23.05 | +8.46% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $10 | $3.81 | +162.47% | 7 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $8 | $11.60 | -31.03% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.25 | $1.53 | -18.30% | 5 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 → $3.5 | $3.98 | -12.06% | 2 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.63 | +22.30% | 1 | Dec 11, 2019 |
Waystar Holding
Jan 9, 2026
Maintains: Buy
Price Target: $49 → $46
Current: $30.58
Upside: +50.43%
Teladoc Health
Jan 9, 2026
Maintains: Neutral
Price Target: $10 → $9
Current: $6.99
Upside: +28.76%
Phreesia
Jan 9, 2026
Maintains: Buy
Price Target: $29 → $25
Current: $16.58
Upside: +50.78%
Health Catalyst
Jan 9, 2026
Maintains: Neutral
Price Target: $3.25 → $2.75
Current: $2.40
Upside: +14.58%
GoodRx Holdings
Jan 9, 2026
Maintains: Buy
Price Target: $5 → $4.5
Current: $2.86
Upside: +57.34%
Evolent Health
Jan 9, 2026
Maintains: Buy
Price Target: $9.5 → $6
Current: $4.01
Upside: +49.63%
Claritev
Jan 9, 2026
Maintains: Buy
Price Target: $80 → $63
Current: $32.42
Upside: +94.32%
Accendra Health
Jan 9, 2026
Maintains: Buy
Price Target: $7 → $4
Current: $2.51
Upside: +59.36%
Cardinal Health
Jan 9, 2026
Upgrades: Buy
Price Target: $190 → $244
Current: $208.26
Upside: +17.16%
McKesson
Sep 24, 2025
Maintains: Buy
Price Target: $820 → $860
Current: $823.98
Upside: +4.37%
Aug 6, 2025
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.95
Upside: +5.26%
May 6, 2025
Maintains: Sell
Price Target: $25 → $30
Current: $32.20
Upside: -6.83%
Apr 22, 2024
Initiates: Buy
Price Target: $25
Current: $23.05
Upside: +8.46%
Aug 9, 2023
Maintains: Neutral
Price Target: $9 → $10
Current: $3.81
Upside: +162.47%
Aug 4, 2023
Downgrades: Sell
Price Target: $7 → $8
Current: $11.60
Upside: -31.03%
Apr 28, 2023
Maintains: Neutral
Price Target: $1.5 → $1.25
Current: $1.53
Upside: -18.30%
Nov 16, 2021
Downgrades: Neutral
Price Target: $7 → $3.5
Current: $3.98
Upside: -12.06%
Dec 11, 2019
Initiates: Outperform
Price Target: $13
Current: $10.63
Upside: +22.30%